Drug Trial Radar · NCT06764485
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
960
Planned (sponsor's estimate)
Start
Mar 13, 2025
Primary completion
Sep 12, 2027
Study completion Jan 19, 2029
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
BMS-986365Drug
Specified dose on specified days
EnzalutamideDrug
Specified dose on specified days
AbirateroneDrug
Specified dose on specified days
DocetaxelDrug
Specified dose on specified days
Predinsone/PrednisoloneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic progression-free survival (rPFS) by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteriaTime frame: Up to 4 years
Locations
227 sites in 26 countries. Site status is shown where the registry gives one.
Local Institution - 0330
Birmingham, Alabama
Local Institution - 0329
Gilbert, Arizona
Local Institution - 0370
Anaheim, California
Local Institution - 0015
La Jolla, California
Local Institution - 0224
Los Alamitos, California
Local Institution - 0016
San Francisco, California
Local Institution - 0411
San Francisco, California
Local Institution - 0238
Aurora, Colorado
Local Institution - 0294
Denver, Colorado
Local Institution - 0419
Lakewood, Colorado
Local Institution - 0413
Washington D.C., District of Columbia
Local Institution - 0426
Lakeland, Florida
Local Institution - 0077
Athens, Georgia
Local Institution - 0048
Chicago, Illinois
Local Institution - 0331
Westwood, Kansas
Local Institution - 0060
Wichita, Kansas
Local Institution - 0054
Baltimore, Maryland
Local Institution - 0019
Baltimore, Maryland
Local Institution - 0344
Frederick, Maryland
Local Institution - 0429
Sewell, New Jersey
Local Institution - 0081
Albuquerque, New Mexico
Local Institution - 0334
Albuquerque, New Mexico
Local Institution - 0197
Buffalo, New York
Local Institution - 0412
Mineola, New York
Local Institution - 0069
New York, New York
Local Institution - 0076
New York, New York
Local Institution - 0085
New York, New York
Local Institution - 0071
New York, New York
Local Institution - 0225
Syracuse, New York
Local Institution - 0056
Columbus, Ohio
Local Institution - 0067
Portland, Oregon
Local Institution - 0416
Portland, Oregon
Local Institution - 0345
Philadelphia, Pennsylvania
Local Institution - 0414
Philadelphia, Pennsylvania
Local Institution - 0057
Philadelphia, Pennsylvania
Local Institution - 0349
Willow Grove, Pennsylvania
Local Institution - 0055
Charleston, South Carolina
Local Institution - 0079
Myrtle Beach, South Carolina
Local Institution - 0335
Nashville, Tennessee
Local Institution - 0018
Austin, Texas
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.